Immunic, Inc. (IMUX) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 90.64M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 16.17M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -117.88M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $90.64M | (m) | $16.17M | $-117.88M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $86.08M | (m) | $11.29M | $-109.64M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $81.98M | (m) | $8.86M | $-103.23M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $84.53M | (m) | $9.54M | $-105.53M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $85.89M | (m) | $7.84M | $-105.27M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $82.84M | (m) | $7.82M | $-101.00M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $80.05M | (m) | $8.53M | $-98.05M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $77.71M | (m) | $8.18M | $-95.80M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $76.14M | (m) | $7.96M | $-93.65M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $78.99M | (m) | $7.87M | $-95.85M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $83.22M | (m) | $7.10M | $-99.22M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $84.67M | (m) | $7.35M | $-133.17M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $81.41M | (m) | $7.58M | $-129.72M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $76.77M | (m) | $7.84M | $-125.30M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $71.25M | (m) | $7.93M | $-119.49M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $68.90M | (m) | $7.51M | $-83.88M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $67.84M | (m) | $6.99M | $-82.15M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $67.04M | (m) | $6.44M | $-80.71M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $61.12M | (m) | $5.95M | $-91.67M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $53.91M | (m) | $5.80M | $-84.13M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $49.47M | (m) | $5.11M | $-79.29M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $43.72M | (m) | $3.97M | $-72.34M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $38.64M | (m) | $2.75M | $-48.97M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $33.49M | (m) | $1.76M | $-42.97M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $29.55M | (m) | $1.25M | $-38.60M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $25.59M | (m) | $6.87M | $-41.38M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $22.51M | (m) | $6.51M | $-37.03M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $35.96M | (m) | $9.92M | $-64.11M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $30.27M | (m) | $9.72M | $-56.74M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $15.16M | (m) | $8.29M | $-37.09M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $24.82M | (m) | $3.74M | $-42.02M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $34.99M | (m) | $4.93M | $-54.25M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $38.70M | (m) | $6.42M | $-54.83M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $39.87M | (m) | $5.77M | $-54.46M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $39.34M | (m) | $5.48M | $-52.66M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $38.01M | (m) | $4.93M | $-49.70M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $35.79M | (m) | $5.09M | $-47.30M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $32.82M | (m) | $4.94M | $-44.30M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $30.05M | (m) | $4.68M | $-41.27M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $28.01M | (m) | $4.48M | $-39.33M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $30.19M | (m) | $4.24M | $-41.43M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $34.88M | (m) | $4.22M | $-46.96M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $39.77M | (m) | $4.03M | $-52.12M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $43.84M | (m) | $3.69M | $-56.25M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $44.43M | (m) | $3.20M | $-56.72M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $42.01M | (m) | $2.88M | $-53.28M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $39.48M | (m) | $2.51M | $-50.34M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $21.79M | (m) | $948.00K | $-31.40M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $5.10M | (m) | $144.00K | $-9.58M | $413.00K | (m) | (m) | -23.20× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B |